UOC di Oncologia Medica - AOU Policlinico S. Orsola Malpighi
Welcome,         Profile    Billing    Logout  
 5 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ardizzoni, Andrea
EDEN, NCT03542461 / 2016-003030-24: Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients ( Trial)

Active, not recruiting
3
125
Europe
Nivolumab 10 MG/ML Intravenous Solution, Best Supportive Care
Gruppo Oncologico Italiano di Ricerca Clinica, Mipharm S.p.A., Bioikos Ambiente Srl, Istituto Toscano Tumori, Temas srl, Bristol Myers Squibb Srl Italia
Squamous Non-small Cell Lung Cancer
01/23
01/23
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
DUPLE, NCT06418087: Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)

Recruiting
2
49
Europe
Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI], Carboplatino AHCL 10 mg/ml Concentrate for solution for infusion, Etoposide 20 mg/ml Concentrate for solution for infusion
Gruppo Oncologico Italiano di Ricerca Clinica
Pulmonary Large-cell Neuroendocrine Carcinoma
12/26
12/26
CeLEBrATE, NCT04730999 / 2019-003798-25: Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer

Completed
2
54
Europe
Etoposide, Carboplatin, Bevacizumab, Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma, Italy, YGHEA, CRO Division of Ecol Studio spa, Dr. Luca Boni U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino - IST NORD CBA
Small Cell Lung Cancer
06/23
06/24
CHANCE, NCT03976518: Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies ( Trial)

Completed
2
43
Europe
Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology, Istituto Toscano Tumori, YGHEA, CRO Division of Ecol Studio spa, Iqvia Pty Ltd, AOU S. Orsola Malpighi - Clinical Trial Office, Silvano Chiapparoli Logistica SpA, Roche SpA
Non-Small Cell Lung Cancer
02/24
02/24
CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Not yet recruiting
2
142
Europe
Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide
Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
08/28
06/29
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
SARCLUNG, NCT06808113: Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC

Active, not recruiting
N/A
40
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Non Small Cell Lung Cancer
10/24
08/27
RECAP, NCT06800586: Tumors and Respiratory System Diseases Due to Air Pollution: New Biomarkers of Exposure and Effects

Not yet recruiting
N/A
300
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
COPD, Lung Cancer (NSCLC), Leukemia
07/26
08/26
Rihawi, Karim
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
CeLEBrATE, NCT04730999 / 2019-003798-25: Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer

Completed
2
54
Europe
Etoposide, Carboplatin, Bevacizumab, Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma, Italy, YGHEA, CRO Division of Ecol Studio spa, Dr. Luca Boni U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino - IST NORD CBA
Small Cell Lung Cancer
06/23
06/24

Download Options